UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.70 +0.68 (+0.87%) GOLD FUTURES
2,389.90 +30.00 (+1.27%) DOW
39,822.81 +264.70 (+0.67%) Bitcoin GBP
51,616.62 +3,222.13 (+6.66%)
MRNS Oct 2024 2.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:09AM EDT. Market open.
| Previous close | 0.8000 |
| Open | 0.9000 |
| Bid | 0.8500 |
| Ask | 1.6500 |
| Strike | 2.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.9000 - 0.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 66 |
Simply Wall St.Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00
Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
ZacksMarinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
RADNOR, Pa., May 08, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.
© 2024 Yahoo. All rights reserved.